CSIMarket
 
Elite Pharmaceuticals Inc  (ELTP)
Other Ticker:  
 
 
Price: $0.5188 $0.00 -0.231%
Day's High: $0.525 Week Perf: 2.75 %
Day's Low: $ 0.49 30 Day Perf: 3.76 %
Volume (M): 1,319 52 Wk High: $ 0.75
Volume (M$): $ 685 52 Wk Avg: $0.32
Open: $0.52 52 Wk Low: $0.12



 Market Capitalization (Millions $) 554
 Shares Outstanding (Millions) 1,068
 Employees 48
 Revenues (TTM) (Millions $) 71
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 3

Elite Pharmaceuticals Inc
Elite Pharmaceuticals Inc. is a global pharmaceutical company that focuses on the development, manufacturing, and commercialization of generic and branded pharmaceutical products. The company has a strong presence in the US, Europe, and Asia, with the majority of its business coming from the United States. Elite Pharmaceuticals has been in operation since 1984 and is headquartered in Northvale, New Jersey.

One of the primary areas of focus for Elite Pharmaceuticals is controlled-release drug delivery systems. The company has developed a proprietary technology that allows for the controlled release of drugs over an extended period of time. This technology has been applied to a wide range of drugs, including opioids for pain management, ADHD medications, and other therapeutics.

Elite Pharmaceuticals manufactures its products through its wholly-owned subsidiary, Elite Laboratories Inc. The company has a state-of-the-art manufacturing facility in Northvale, New Jersey, which is approved by the US Food and Drug Administration (FDA) and has been audited by regulatory agencies in Europe and Asia.

In addition to its focus on controlled-release drug delivery systems, Elite Pharmaceuticals also has a pipeline of new products in development. The company collaborates with other pharmaceutical companies and research institutions to develop new therapeutics for a variety of indications.

Elite Pharmaceuticals has a strong track record of commercial success. The company has a portfolio of more than 20 products under various stages of development and has successfully launched several products in the US market. Elite Pharmaceuticals has also received numerous accolades and awards for its innovative drug delivery systems and manufacturing capabilities.

The company's leadership team is led by CEO and President, Nasrat Hakim, who has over 30 years of experience in the pharmaceutical industry. The company also has a team of experienced executives, scientists, and engineers who are dedicated to advancing Elite Pharmaceuticals' mission of improving human health through innovative drug delivery systems.


   Company Address: 165 Ludlow Avenue Northvale 7647 NJ
   Company Phone Number: 750-2646   Stock Exchange / Ticker: ELTP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
RMTI   -5.94%    
NEPH   -0.59%    
• View Complete Report
   



Elite Pharmaceuticals Inc

Elite Pharmaceuticals Inc. Boasts Impressive Earnings Thanks to $1.33 Million in Tax Provisions

/>Elite Pharmaceuticals Inc., a major player in the pharmaceutical industry, has defied industry trends by reporting remarkable financial results for the fiscal year ending March 31, 2024. While most of its competitors witnessed a decline in revenues, ELTP has witnessed substantial revenue growth and improved bottom-line figures. Furthermore, the company's stock has been on an upward trajectory, reflecting the market's confidence in its performance.
Earnings and Revenue:
ELTP reported an income per share of $0.01 for the financial year ending March 31, 2024, which remained steady compared to the previous year's results. Notably, this is a significant improvement from the $0.00 per share reported in the prior reporting season. Revenue also surged by an impressive 127.929% to $19.12 million, compared to $8.39 million in the previous year. Sequentially, the company achieved a 27.108% revenue growth from the previous reporting season, where revenue stood at $15.04 million.

Elite Pharmaceuticals Inc

Improved headline: Elite Pharmaceuticals Inc's Strong Revenue Growth Fails to Offset Decline in Net Income



Elite Pharmaceuticals Inc, a leading pharmaceutical company, recently released its financial results for the third quarter of 2024, showcasing a mixed performance. While the company achieved balanced books with a per-share value of $0.00, it faced a decline in net income compared to the same period last year. Analysts attribute the decline to the absence of an income tax benefit.
One positive aspect of the report was the substantial growth in revenue. Elite Pharmaceuticals Inc recorded a strong 68.637% increase, reaching $15.04 million in the third quarter, up from $8.92 million a year ago. Sequentially, the company's revenue advanced by 11.854% from $13.45 million in the preceding reporting period.







Elite Pharmaceuticals Inc's Segments
Manufacturing    100.15 % of total Revenue
Licensing    3.6 % of total Revenue
Abbreviated New Drug Applications    103.75 % of total Revenue
Abbreviated New Drug Applications Manufacturing    100.15 % of total Revenue
Abbreviated New Drug Applications Licensing    3.6 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com